

# Alliance for Biosecurity

Office of the Secretary and Legal Counsel

1500 K Street, NW, Suite 1100

Washington, DC 20005

Telephone: 1.202.230.5133 • Facsimile: 1.202.842.8465

March 4, 2013

The Honorable Mike Rogers

2112 Rayburn House Office Building

Washington, DC 20515

Dear Representative Rogers:

On behalf of the Alliance for Biosecurity, I write in strong support of the Pandemic All-Hazards Preparedness Reauthorization Act of 2013 (H.R. 307). The Alliance for Biosecurity is a collaboration of pharmaceutical and biotechnology companies working to develop medical countermeasures (MCMs) to prevent and treat diseases associated with bioterrorism and emerging infectious diseases. We are extremely pleased that both the House and the Senate have taken this legislation up so expeditiously this Congress and hope for quick House passage of the amended bill.

As you know, the chemical, biological, radiological, and nuclear (CBRN) threat is real and growing. It is critical that the country continue ongoing efforts to develop, procure, and stockpile MCMs to both deter an attack and protect our citizens should a bioterrorism event occur. The Congressionally-established Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism 2008 report predicted that "it is more likely than not that a weapon of mass destruction will be used in a terrorist attack somewhere in the world by the end of 2013." There is a limited commercial market for MCMs; consequently, without adequate advanced development and stockpiling funding, companies have neither the incentive nor the ability to invest in these life-saving therapies.

Reauthorization of PAHPA and Project BioShield is critical to ensuring the sustainability of the MCM enterprise. We urge you to pass the amended H.R. 307 without delay to ensure that our nation remains prepared to face such threats.

Respectfully submitted on behalf of the Alliance for Biosecurity,



The Alliance for Biosecurity

*Secretariat and Legal Counsel*

Bavarian-Nordic • Cangene Corporation • CUBRC Inc. • Elusys Therapeutics •

Emergent BioSolutions • PharmAthene • Siga Technologies •

Unither Virology LLC, a subsidiary of United Therapeutics Corporation

**ASSOCIATE MEMBERS**

Battelle Memorial Institute • Lovelace Respiratory Research Institute • Southern Research Institute